rezpegaldesleukin
rezpegaldesleukin: sourced relationships with 1 company · 4 clinical trials tracked.
rezpegaldesleukin evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could rezpegaldesleukin → NKTR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| NEKTAR THERAPEUTICS (NKTR) Moderate to Severe Atopic Dermatitis; Moderate-to-Severe Ato… | Phase 3 |
Clinical Trial Registry Records (4)
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to- Severe Atopic Dermatitis
Primary endpoint: US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Primary endpoint: US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
Primary endpoint: Percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 36
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)
Primary endpoint: Mean percent change in the Eczema Area and Severity Index (EASI) from baseline at Week 16
Frequently asked questions
Which companies have sourced relationships with rezpegaldesleukin?
rezpegaldesleukin has dated SEC/FDA relationship records for NEKTAR THERAPEUTICS.
How many clinical trials involve rezpegaldesleukin?
BioSniper tracks 4 clinical trials involving rezpegaldesleukin.